- It's shaping up to be another ugly session for InVivo Therapeutics (NVIV.OB -28.5%) as doubts about the timeline and clinical plan for the company's biopolymer scaffolding persist.
- The stock is now down 64% since Friday.
- SA contributor and Zacks analyst Jason Napodano penned a cautious (but generally upbeat) piece on the shares Tuesday, noting that the "more realistic clinical guidance from the new interim CEO [is] refreshing."
- Nevertheless, Napodano says he has been removed from the list of analysts on the company's website.
InVivo tumbles again, now off by two-thirds in four days
Aug 28 2013, 10:42 ET